ClinicalTrials.gg
CompletedNCT03000673Updated Dec 29, 2020Results posted

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

A Phase 1/2 interventional study of Enoxaparin and unfractionated heparin (UFH) in Antithrombotic, sponsored by Bristol-Myers Squibb. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-29.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To investigate safety of Single Doses of BMS-986177 in Patients with End Stage Renal Disease treated with hemodialysis

02

Conditions studied

  • Antithrombotic
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Subjects with ESRD treated with hemodialysis 3 times a week for at least 3 months prior enrollment.
  • Women of (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study treatment.
  • Women must not be breastfeeding
  • Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of for the duration of treatment with study treatment(s) BMS-986177 plus 5 half-lives of study treatment (2 days) plus 30 days (duration of ovulatory cycle) for a total of 32 days post-treatment completion
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatment(s) BMS-986177 plus 5 half-lives of the study treatment plus 90 days (duration of sperm turnover) for a total of 92 days post-treatment completion. In addition, male participants must be willing to refrain from sperm donation during this time.

Exclusion criteria

Exclusion Criteria:

  • Subjects receiving dialysis through central venous catheters
  • History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric and/or neurological disease in the past 3 months
  • Current or recent (within 3 months of study drug administration) gastrointestinal disease or surgery, which by the judgment of the Investigator, may increase a subject's risk of gastrointestinal bleeding or interfere with absorption of study drug (e.g., peptic or gastric ulcer disease, severe gastritis, history of gastrointestinal surgery).
  • Any major surgery within 12 weeks of study drug administration
  • History of significant head injury within the last 2 years, including subjects with base of skull fractures

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Dose Sequence 1

    UFH, BMS-986177 - dose 1, BMS-986177 - dose 2, Enoxaparin

    Drug: Enoxaparin · Drug: unfractionated heparin (UFH) · Drug: BMS-986177

  • Active comparator
    Dose Sequence 2

    BMS-986177 - dose 1, Enoxaparin, UFH, BMS-986177 - dose 2

    Drug: Enoxaparin · Drug: unfractionated heparin (UFH) · Drug: BMS-986177

  • Active comparator
    Dose Sequence 3

    BMS-986177 - dose 2, UFH, Enoxaparin, BMS-986177 - dose 1

    Drug: Enoxaparin · Drug: unfractionated heparin (UFH) · Drug: BMS-986177

  • Active comparator
    Dose Sequence 4

    Enoxaparin, BMS-986177 - dose 2, BMS-986177 - dose 1, UFH

    Drug: Enoxaparin · Drug: unfractionated heparin (UFH) · Drug: BMS-986177

Interventions

06

What researchers measure

Primary outcomes

  1. The Number of Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation and Death

    Safety and tolerability of single oral doses of BMS-986177 in patients with end-stage renal disease (ESRD) on chronic hemodialysis (HD) treatment as measured by the number of participants with adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation and death

    Time frame: From the date of patient's written consent to participate in study until 30 days after discontinuation of dosing or patient's participation in study (up to October 2017)

  2. The Number of Participants Marked Abnormalities in Clinical Laboratory Tests : Hematology I; Hematology II; Coagulation

    HEMATOLOGY I; HEMOGLOBIN HB G/DL LOW \< 0.85\*PRE-RX; HEMATOCRIT HCT % LOW \< 0.85\*PRE-RX; PLATELET COUNT PLAT X10\*9 C/L LOW \< 0.85\*LLN IF PRE-RX IS MISSING; \< 0.85\*LLN IF PRE-RX \>= LLN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; HIGH \> 1.5\*ULN; HEMATOLOGY II; LEUKOCYTES WBC X10\*3 C/UL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF LLN \<= PRE-RX \<= ULN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.2\*ULN IF PRE-RX IS MISSING; \> 1.2\*ULN IF LLN \<= PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN; NEUTROPHILS (ABSOLUTE) NEUTA X10\*3 C/UL LOW \< 1.5 IF PRE-RX IS MISSING; \< 1.5 IF PRE-RX \>= 1.5; \< 0.85\*PRE-RX IF; PRE-RX \< 1.5; LYMPHOCYTES (ABSOLUTE) LYMPA X10\*3 C/UL LOW \< 0.75; HIGH \> 7.5; MONOCYTES (ABSOLUTE) MONOA X10\*3 C/UL HIGH \> 2; BASOPHILS (ABSOLUTE) BASOA X10\*3 C/UL HIGH \> 0.4; EOSINOPHILS (ABSOLUTE) EOSA X10\*3 C/UL HIGH \> 0.75; COAGULATION: PROTHROMBIN TIME (PT) PT SEC HIGH \> 1.5\*ULN; APTT APTT SEC HIGH \> 1.5\*ULN; INTL NORMALIZED RATIO (INR) INR FRACTION HIGH \> 1.5\*ULN;

    Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.

  3. The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.) : Liver and Kidney Function

    LIVER \& KIDNEY FUNCTION; ALKALINE PHOSPHATASE (ALP) ALP U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; ASPARTATE AMINOTRANSFERASE (AST) AST U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; ALANINE AMINOTRANSFERASE (ALT) ALT U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BILIRUBIN, TOTAL TBILI MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BILIRUBIN, DIRECT DBILI MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BLOOD UREA NITROGEN BUN MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.2\*PRE-RX IF PRE-RX \> ULN; CREATININE CREAT MG/DL HIGH \> 1.5\*ULN IF PRE-RX IS MISSING; \> 1.5\*ULN IF PRE-RX \<= ULN; \> 1.33\*PRE-RX IF PRE-RX \> ULN;

    Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.

  4. The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Electrolytes

    ELECTROLYTES: SODIUM, SERUM NA MEQ/L LOW \< 0.95\*LLN IF PRE-RX IS MISSING; \< 0.95\*LLN IF PRE-RX \>= LLN; \< 0.95\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.05\*ULN IF PRE-RX IS MISSING; \> 1.05\*ULN IF PRE-RX \<= ULN; \> 1.05\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; POTASSIUM, SERUM K MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; CHLORIDE, SERUM CL MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN;

    Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge

  5. The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Electrolytes (Cont.)

    ELECTROLYTES (CONT.): CALCIUM, TOTAL CA MG/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; PHOSPHORUS, INORGANIC PHOS MG/DL LOW \< 0.85\*LLN IF PRE-RX IS MISSING; \< 0.85\*LLN IF PRE-RX \>= LLN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; MAGNESIUM, SERUM MG MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN

    Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.

  6. The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Other Chemistry Testing

    GLUCOSE, FASTING SERUM GLUCF MG/DL LOW \< 0.8\*LLN IF PRE-RX IS MISSING; \< 0.8\*LLN IF PRE-RX \>= LLN; \< 0.8\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.3\*ULN IF PRE-RX IS MISSING \> 1.3\*ULN IF PRE-RX \<= ULN; \> 2\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; PROTEIN, TOTAL TPRO G/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; ALBUMIN ALB G/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; CREATINE KINASE (CK) CK U/L HIGH \> 1.5\*ULN IF PRE-RX IS MISSING; \> 1.5\*ULN IF PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN; URIC ACID URIC MG/DL HIGH \> 1.2\*ULN IF PRE-RX IS MISSING; \> 1.2\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; LACTATE DEHYDR (LD) LD U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN

    Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.

  7. The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.) : Urinalysis I, Special Studies

    URINALYSIS I; BLOOD, URINE UBLD N/A HIGH \>= 2 IF PRE-RX IS MISSING; \>= 2 IF PRE-RX \< 1; \>= 2 IF PRE-RX \>= 1 SPECIAL STUDIES; OCCULT BLOOD SCREEN, FECES OCBLD N/A HIGH NEGATIVE PRE-RX CHANGING TO POSITIVE

    Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.

  8. The Change From Baseline in Electrocardiogram (ECG) Parameters: Mean Heart Rate

    Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.

    Time frame: Days -3 to -1, Days 1, 5, 8, and 12.

  9. The Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, Aggregate

    Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.

    Time frame: Days -3 to -1, Days 1, 5, 8, and 12.

  10. The Change From Baseline in Electrocardiogram (ECG) Parameters: QRS Duration, Aggregate

    Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.

    Time frame: Days -3 to -1, Days 1, 5, 8, and 12.

  11. The Change From Baseline in Electrocardiogram (ECG) Parameters: QT Interval, Aggregate

    Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.

    Time frame: Days -3 to -1, Days 1, 5, 8, and 12.

  12. The Change From Baseline in Electrocardiogram (ECG) Parameters: QTcF Interval, Aggregate

    QTcF = QT corrected for heart rate using the Fridericia formula Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.

    Time frame: Days -3 to -1, Days 1, 5, 8, and 12

  13. The Change From Baseline in Vital Signs: Diastolic Blood Pressure

    Time frame: Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15

  14. The Change From Baseline in Vital Signs: Systolic Blood Pressure (mm Hg)

    Time frame: Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15

  15. The Change From Baseline in Vital Signs: Heart Rate (Beats/Min)

    Time frame: Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15

Secondary outcomes

  1. Pharmacokinetic Parameters of BMS-986177: Cmax

    Cmax: Maximum observed plasma concentration

    Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence

  2. Pharmacokinetic Parameters of BMS-986177: Tmax

    Time of maximum observed plasma concentration

    Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence

  3. Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T), AUC (0-24)

    AUC(0-T) Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration AUC(0-24) Area under the plasma concentration-time curve from time zero to 24 hours

    Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence

  4. Pharmacokinetic Parameters of BMS-986177: fu

    Fraction of unbound drug

    Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence

  5. Pharmacokinetic Parameters of BMS-986177: Cmaxfu

    Maximum observed plasma concentration of free drug

    Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence

  6. Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T)fu

    AUC(0-T)fu Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of free drug

    Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence

  7. Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (3-7)

    AUC (3-7) : Area under the plasma concentration-time curve from 3 to 7 hours (ie, during dialysis. Determined from blood samples entering and exiting the dialyzer)

    Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence

07

Results

Posted Dec 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneSequence ABCDSequence BDACSequence CADBSequence DCBA
Started7979
Completed6979
Not completed1000
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryThe Number of Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation and Death

Safety and tolerability of single oral doses of BMS-986177 in patients with end-stage renal disease (ESRD) on chronic hemodialysis (HD) treatment as measured by the number of participants with adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation and death

Time frame:
From the date of patient's written consent to participate in study until 30 days after discontinuation of dosing or patient's participation in study (up to October 2017)
Reported as:
Number · Participants
The Number of Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation and Death
ParticipantsTreatment BTreatment CTreatment DTreatment A
Adverse Events4432
Serious Adverse Events0000
Adverse Events Leading to Discontinuations0000
Deaths0000
PrimaryThe Number of Participants Marked Abnormalities in Clinical Laboratory Tests : Hematology I; Hematology II; Coagulation

HEMATOLOGY I; HEMOGLOBIN HB G/DL LOW \< 0.85\*PRE-RX; HEMATOCRIT HCT % LOW \< 0.85\*PRE-RX; PLATELET COUNT PLAT X10\*9 C/L LOW \< 0.85\*LLN IF PRE-RX IS MISSING; \< 0.85\*LLN IF PRE-RX \>= LLN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; HIGH \> 1.5\*ULN; HEMATOLOGY II; LEUKOCYTES WBC X10\*3 C/UL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF LLN \<= PRE-RX \<= ULN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.2\*ULN IF PRE-RX IS MISSING; \> 1.2\*ULN IF LLN \<= PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN; NEUTROPHILS (ABSOLUTE) NEUTA X10\*3 C/UL LOW \< 1.5 IF PRE-RX IS MISSING; \< 1.5 IF PRE-RX \>= 1.5; \< 0.85\*PRE-RX IF; PRE-RX \< 1.5; LYMPHOCYTES (ABSOLUTE) LYMPA X10\*3 C/UL LOW \< 0.75; HIGH \> 7.5; MONOCYTES (ABSOLUTE) MONOA X10\*3 C/UL HIGH \> 2; BASOPHILS (ABSOLUTE) BASOA X10\*3 C/UL HIGH \> 0.4; EOSINOPHILS (ABSOLUTE) EOSA X10\*3 C/UL HIGH \> 0.75; COAGULATION: PROTHROMBIN TIME (PT) PT SEC HIGH \> 1.5\*ULN; APTT APTT SEC HIGH \> 1.5\*ULN; INTL NORMALIZED RATIO (INR) INR FRACTION HIGH \> 1.5\*ULN;

Time frame:
At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.
Reported as:
Count of participants · Participants
The Number of Participants Marked Abnormalities in Clinical Laboratory Tests : Hematology I; Hematology II; Coagulation
ParticipantsTreatment BTreatment CTreatment DTreatment A
Hematology I Hemoglobin (G/DL) Abnormal low3321
Hematocrit (%) Abnormal low3422
Platelet Count (X10*9 C/L) Abnormal low1121
Leukocytes (X10*3 C/UL) Abnormal low2102
Leukocytes (X10*3 C/UL): Abnormal high0011
Neutrophils (Absolute) (X10*3 C/UL)0021
Lymphocytes (Absolute) (X10*3 C/UL) Abnormal low3435
Monocytes (Absolute) (X10*3 C/UL) Abnormal high0000
Basophils (Absolute) (X10*3 C/UL) Abnormal high0000
Eosinophils (Absolute) (X10*3 C/UL)1121
Prothrombin time (PT) (sec): Abnormal high1120
APTT (sec): Abnormal high42510
APTT (sec): Not reported1001
INR (fraction): Abnormal high0000
PrimaryThe Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.) : Liver and Kidney Function

LIVER \& KIDNEY FUNCTION; ALKALINE PHOSPHATASE (ALP) ALP U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; ASPARTATE AMINOTRANSFERASE (AST) AST U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; ALANINE AMINOTRANSFERASE (ALT) ALT U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BILIRUBIN, TOTAL TBILI MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BILIRUBIN, DIRECT DBILI MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BLOOD UREA NITROGEN BUN MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.2\*PRE-RX IF PRE-RX \> ULN; CREATININE CREAT MG/DL HIGH \> 1.5\*ULN IF PRE-RX IS MISSING; \> 1.5\*ULN IF PRE-RX \<= ULN; \> 1.33\*PRE-RX IF PRE-RX \> ULN;

Time frame:
At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.
Reported as:
Count of participants · Participants
The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.) : Liver and Kidney Function
ParticipantsTreatment BTreatment CTreatment DTreatment A
ALP (U/L) Abnormal high0001
AST (U/L) Abnormal high0000
AST (U/L) Not reported0010
ALT (U/L) Abnormal high0010
Bilirubin, Total (MG/DL) Abnormal high0010
Bilirubin, Direct (MG/DL) Abnormal high1113
Bilirubin, Direct (MG/DL), Not reported1010
Blood Urea Nitrogen (MG/DL) Abnormal high0110
Creatinine (MG/DL) Abnormal high0000
Creatinine (MG/DL) Not reported1001
PrimaryThe Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Electrolytes

ELECTROLYTES: SODIUM, SERUM NA MEQ/L LOW \< 0.95\*LLN IF PRE-RX IS MISSING; \< 0.95\*LLN IF PRE-RX \>= LLN; \< 0.95\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.05\*ULN IF PRE-RX IS MISSING; \> 1.05\*ULN IF PRE-RX \<= ULN; \> 1.05\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; POTASSIUM, SERUM K MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; CHLORIDE, SERUM CL MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN;

Time frame:
At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge
Reported as:
Count of participants · Participants
The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Electrolytes
ParticipantsTreatment BTreatment CTreatment DTreatment A
Sodium, Serum (MEQ/L), Abnormal low0000
Sodium, Serum (MEQ/L), Abnormal high0000
Potassium, Serum (MEQ/L), Abnormal low0000
Potassium, Serum (MEQ/L), Abnormal high0111
Potassium, Serum (MEQ/L), Not reported0010
Chloride, Serum (MEQ/L) Abnormal low0000
Chloride, Serum (MEQ/L) Abnormal high0000
Chloride, Serum (MEQ/L) Not reported0001
PrimaryThe Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Electrolytes (Cont.)

ELECTROLYTES (CONT.): CALCIUM, TOTAL CA MG/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; PHOSPHORUS, INORGANIC PHOS MG/DL LOW \< 0.85\*LLN IF PRE-RX IS MISSING; \< 0.85\*LLN IF PRE-RX \>= LLN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; MAGNESIUM, SERUM MG MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN

Time frame:
At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.
Reported as:
Count of participants · Participants
The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Electrolytes (Cont.)
ParticipantsTreatment BTreatment CTreatment DTreatment A
Calcium, Total (MG/DL) Abnormal low0001
Calcium, Total (MG/DL) Abnormal high0000
Phosphorus, Inorganic (MG/DL) Abnormal low0112
Phosphorus, Inorganic (MG/DL) Abnormal high0000
Magnesium, Serum (MEQ/L), Abnormal low0101
Magnesium, Serum (MEQ/L), Abnormal high0000
Magnesium, Serum (MEQ/L), Not reported0010
PrimaryThe Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Other Chemistry Testing

GLUCOSE, FASTING SERUM GLUCF MG/DL LOW \< 0.8\*LLN IF PRE-RX IS MISSING; \< 0.8\*LLN IF PRE-RX \>= LLN; \< 0.8\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.3\*ULN IF PRE-RX IS MISSING \> 1.3\*ULN IF PRE-RX \<= ULN; \> 2\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; PROTEIN, TOTAL TPRO G/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; ALBUMIN ALB G/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; CREATINE KINASE (CK) CK U/L HIGH \> 1.5\*ULN IF PRE-RX IS MISSING; \> 1.5\*ULN IF PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN; URIC ACID URIC MG/DL HIGH \> 1.2\*ULN IF PRE-RX IS MISSING; \> 1.2\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; LACTATE DEHYDR (LD) LD U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN

Time frame:
At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.
Reported as:
Count of participants · Participants
The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Other Chemistry Testing
ParticipantsTreatment BTreatment CTreatment DTreatment A
Glucose, Fasting serum (MG/DL) Abnormal low0011
Glucose, Fasting serum (MG/DL) Abnormal high2244
Protein, Total (G/DL) Abnormal low0011
Protein, Total (G/DL) Abnormal high0000
Albumin (G/DL) Abnormal low0012
Creatine Kinase (CK) (U/L) Abnormal high0000
Creatine Kinase (CK) (U/L) Not reported0010
Uric Acid (MG/DL) Abnormal High0000
LD (U/L) Abnormal high0030
LD (U/L) Not reported0010
PrimaryThe Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.) : Urinalysis I, Special Studies

URINALYSIS I; BLOOD, URINE UBLD N/A HIGH \>= 2 IF PRE-RX IS MISSING; \>= 2 IF PRE-RX \< 1; \>= 2 IF PRE-RX \>= 1 SPECIAL STUDIES; OCCULT BLOOD SCREEN, FECES OCBLD N/A HIGH NEGATIVE PRE-RX CHANGING TO POSITIVE

Time frame:
At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.
Reported as:
Count of participants · Participants
The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.) : Urinalysis I, Special Studies
ParticipantsTreatment BTreatment CTreatment DTreatment A
Blood, Urine (N/A) Abnormal high1100
Occult Blood Screen, Feces (N/A) Abnormal high0000
PrimaryThe Change From Baseline in Electrocardiogram (ECG) Parameters: Mean Heart Rate

Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.

Time frame:
Days -3 to -1, Days 1, 5, 8, and 12.
Reported as:
Mean · Beats/min
The Change From Baseline in Electrocardiogram (ECG) Parameters: Mean Heart Rate
Beats/minTreatment BTreatment CTreatment DTreatment A
Day 11.8 ± 8.61.4 ± 5.10.4 ± 8.1-0.1 ± 5.4
Day 5-2.1 ± 6.92.0 ± 10.82.0 ± 8.11.6 ± 5.9
Day 80.0 ± 6.9-2.8 ± 6.12.3 ± 4.74.0 ± 9.8
Day 120.4 ± 6.03.9 ± 9.50.8 ± 2.91.4 ± 9.5
PrimaryThe Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, Aggregate

Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.

Time frame:
Days -3 to -1, Days 1, 5, 8, and 12.
Reported as:
Mean · msec
The Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, Aggregate
msecTreatment BTreatment CTreatment DTreatment A
Day 1-1.3 ± 9.9-25.0 ± 67.8-6.9 ± 12.613.6 ± 26.3
Day 512.6 ± 21.2-5.8 ± 8.9-5.1 ± 11.8-25.4 ± 66.5
Day 8-1.2 ± 19.312.7 ± 25.5-22.6 ± 70.3-3.4 ± 27.2
Day 12-27.7 ± 67.9-5.6 ± 8.78.8 ± 12.4-2.6 ± 8.7
PrimaryThe Change From Baseline in Electrocardiogram (ECG) Parameters: QRS Duration, Aggregate

Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.

Time frame:
Days -3 to -1, Days 1, 5, 8, and 12.
Reported as:
Mean · msec
The Change From Baseline in Electrocardiogram (ECG) Parameters: QRS Duration, Aggregate
msecTreatment BTreatment CTreatment DTreatment A
Day 1-1.1 ± 6.75.7 ± 6.2-0.2 ± 3.3-3.1 ± 11.0
Day 5-0.3 ± 14.8-0.2 ± 4.6-0.2 ± 4.60.6 ± 4.8
Day 8-0.2 ± 4.2-1.8 ± 8.8-0.7 ± 6.00.3 ± 8.6
Day 120.9 ± 6.3-0.1 ± 9.3-0.7 ± 9.72.0 ± 7.0
PrimaryThe Change From Baseline in Electrocardiogram (ECG) Parameters: QT Interval, Aggregate

Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.

Time frame:
Days -3 to -1, Days 1, 5, 8, and 12.
Reported as:
Mean · msec
The Change From Baseline in Electrocardiogram (ECG) Parameters: QT Interval, Aggregate
msecTreatment BTreatment CTreatment DTreatment A
Day 1-3.7 ± 22.2-1.6 ± 20.8-3.1 ± 24.03.9 ± 23.2
Day 58.4 ± 19.3-7.4 ± 20.1-2.8 ± 22.05.6 ± 15.9
Day 8-1.8 ± 21.312.0 ± 11.9-3.6 ± 24.0-7.4 ± 26.8
Day 120.7 ± 20.1-14.9 ± 28.2-0.7 ± 10.8-2.2 ± 20.4
PrimaryThe Change From Baseline in Electrocardiogram (ECG) Parameters: QTcF Interval, Aggregate

QTcF = QT corrected for heart rate using the Fridericia formula Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.

Time frame:
Days -3 to -1, Days 1, 5, 8, and 12
Reported as:
Mean · msec
The Change From Baseline in Electrocardiogram (ECG) Parameters: QTcF Interval, Aggregate
msecTreatment BTreatment CTreatment DTreatment A
Day 1-3.2 ± 15.31.7 ± 13.5-1.0 ± 16.55.7 ± 15.7
Day 55.1 ± 7.6-4.9 ± 11.8-0.6 ± 13.19.9 ± 14.7
Day 8-1.3 ± 17.16.2 ± 6.70.3 ± 19.7-2.1 ± 18.5
Day 122.1 ± 15.0-9.9 ± 22.80.8 ± 7.11.0 ± 10.5
PrimaryThe Change From Baseline in Vital Signs: Diastolic Blood Pressure
Time frame:
Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15
Reported as:
Mean · mmHg
The Change From Baseline in Vital Signs: Diastolic Blood Pressure
mmHgTreatment BTreatment CTreatment DTreatment A
3 hours post Hemodialysis-3.7 ± 10.50.2 ± 10.90.1 ± 9.00.5 ± 9.3
24 hours post dose-2.8 ± 9.9-2.2 ± 8.7NA ± NANA ± NA
PrimaryThe Change From Baseline in Vital Signs: Systolic Blood Pressure (mm Hg)
Time frame:
Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15
Reported as:
Mean · mmHg
The Change From Baseline in Vital Signs: Systolic Blood Pressure (mm Hg)
mmHgTreatment BTreatment CTreatment DTreatment A
3 hours post hemodialysis-6.6 ± 28.21.1 ± 24.9-0.2 ± 17.0-5.8 ± 18.0
24 hours post dose-8.4 ± 23.7-9.2 ± 17.6NA ± NANA ± NA
SecondaryPharmacokinetic Parameters of BMS-986177: Cmax

Cmax: Maximum observed plasma concentration

Time frame:
Either Day 1, 5, 8, or 12 depending on the randomization sequence
Reported as:
Mean · ng/mL
Pharmacokinetic Parameters of BMS-986177: Cmax
ng/mLTreatment BTreatment C
Pharmacokinetic Parameters of BMS-986177: Cmax1120 ± 391.83342 ± 922.2
PrimaryThe Change From Baseline in Vital Signs: Heart Rate (Beats/Min)
Time frame:
Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15
Reported as:
Mean · beats/min
The Change From Baseline in Vital Signs: Heart Rate (Beats/Min)
beats/minTreatment BTreatment CTreatment DTreatment A
3 hours post hemodialysis4.9 ± 9.44.0 ± 7.44.5 ± 6.53.3 ± 8.9
24 hours post dose4.2 ± 5.61.1 ± 7.0NA ± NANA ± NA
SecondaryPharmacokinetic Parameters of BMS-986177: Tmax

Time of maximum observed plasma concentration

Time frame:
Either Day 1, 5, 8, or 12 depending on the randomization sequence
Reported as:
Mean · h
Pharmacokinetic Parameters of BMS-986177: Tmax
hTreatment BTreatment C
Pharmacokinetic Parameters of BMS-986177: Tmax4.531 ± 0.9334.855 ± 1.042
SecondaryPharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T), AUC (0-24)

AUC(0-T) Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration AUC(0-24) Area under the plasma concentration-time curve from time zero to 24 hours

Time frame:
Either Day 1, 5, 8, or 12 depending on the randomization sequence
Reported as:
Mean · ng.h/mL
Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T), AUC (0-24)
ng.h/mLTreatment BTreatment C
AUC (0-T)10406.6 ± 4551.736112.9 ± 19802.5
AUC (0-24)10533.4 ± 4492.834028.0 ± 12191.9
SecondaryPharmacokinetic Parameters of BMS-986177: fu

Fraction of unbound drug

Time frame:
Either Day 1, 5, 8, or 12 depending on the randomization sequence
Reported as:
Mean · Percentage
Pharmacokinetic Parameters of BMS-986177: fu
PercentageTreatment BTreatment C
Pharmacokinetic Parameters of BMS-986177: fu7.644 ± 1.2577.868 ± 1.481
SecondaryPharmacokinetic Parameters of BMS-986177: Cmaxfu

Maximum observed plasma concentration of free drug

Time frame:
Either Day 1, 5, 8, or 12 depending on the randomization sequence
Reported as:
Mean · ng/mL
Pharmacokinetic Parameters of BMS-986177: Cmaxfu
ng/mLTreatment BTreatment C
Pharmacokinetic Parameters of BMS-986177: Cmaxfu84.32 ± 30.14257.9 ± 70.40
SecondaryPharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T)fu

AUC(0-T)fu Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of free drug

Time frame:
Either Day 1, 5, 8, or 12 depending on the randomization sequence
Reported as:
Mean · ng.h/mL
Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T)fu
ng.h/mLTreatment BTreatment C
Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T)fu783.5 ± 342.12782.2 ± 1537.7
SecondaryPharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (3-7)

AUC (3-7) : Area under the plasma concentration-time curve from 3 to 7 hours (ie, during dialysis. Determined from blood samples entering and exiting the dialyzer)

Time frame:
Either Day 1, 5, 8, or 12 depending on the randomization sequence
Reported as:
Mean · ng.h/mL
Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (3-7)
ng.h/mLTreatment BTreatment C
Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (3-7)2847.4 ± 1039.18558.1 ± 2509.1

Adverse events

Collected over From the date of the patient's written consent to participate in the study until 30 days after discontinuation of dosing. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/32 (0%)0/32 (0%)0/32 (0%)
Treatment B0/32 (0%)0/32 (0%)0/32 (0%)
Treatment C0/31 (0%)0/31 (0%)0/31 (0%)
Treatment D0/31 (0%)0/31 (0%)0/31 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Seq ABCDSeq BDACSeq CADBSeq DCBATotal
Mean55.1 ± 7.355.6 ± 6.652.0 ± 12.451.7 ± 9.953.6 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Seq ABCDSeq BDACSeq CADBSeq DCBATotal
Female153312
Male644620
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Seq ABCDSeq BDACSeq CADBSeq DCBATotal
Hispanic or Latino00000
Not Hispanic or Latino797932
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Seq ABCDSeq BDACSeq CADBSeq DCBATotal
White10113
Black or African American696829
08

Study locations

3 sites
  • Davita Clinical Research
    Lakewood, Colorado 80228, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Davita Clinical Research
    Minneapolis, Minnesota 55404, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Oct 2017, 5 months.

Results were first posted in Dec 2020, 3 years 2 months after primary completion. A results delay was requested in Nov 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2016
First posted
Dec 22, 2016
StartActual
May 23, 2017
Primary completionActual
Oct 23, 2017
CompletionActual
Oct 23, 2017
Results delay requested
Nov 7, 2018
Results first posted
Dec 29, 2020
Last update
Dec 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03000673
Responsible party
Sponsor
First posted
Dec 22, 2016
Start date
May 23, 2017
Primary completion
Oct 23, 2017
Completion
Oct 23, 2017
Results posted
Dec 29, 2020
Last update
Dec 29, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion